Would rather be SCUBA diving
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$CTYX now Curative Biotechnologies, Inc.
CTYX will grow Organically with drug acquisitions and licensing deals like it has the past few months. Connectyx name is not indicative of what they do and has nothing to do with Orphan Drugs. Curative Does. so name change and Ticker Change most likely coming in a PR.
No CEO would go to the expense of Buying a Publicly traded company like CTYX. Pay all the money to clean it up and get it Pink and then merge it into their own private company.
Are you new to OTC Stocks and mergers? Shares get converted to new Name and Ticker we don't lose anything.
Can someone get a screenshot of this? FL SOS not shwoing for most peeps.
$NIO profit taking and Citron shorting probs.
$JADA .12 check VERT and OTCX ask!
$JADA stick to JADA on this board.
Get some new material
JADA your back got smashed all weekend
CTYX no stock promotion only legit DD.
CTYX PRV's sold daily for tens of Millions. That's how to fund a company growth spurt.
http://www.globenewswire.com/news-release/2020/07/27/2068182/0/en/Lumos-Pharma-Announces-Sale-of-Priority-Review-Voucher.html
Lumos Pharma Announces Sale of Priority Review Voucher
Email Print Friendly Share
July 27, 2020 16:05 ET | Source: Lumos Pharma, Inc.
AUSTIN, Texas, July 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that it has entered into a definitive agreement to sell its Priority Review Voucher (PRV) to Merck, known as MSD outside the United States and Canada.
The PRV was granted in conjunction with the approval by the U.S. Food and Drug Administration (FDA) of ERVEBO®, a vaccine developed by the Company’s licensee, Merck, for the prevention of the Zaire Ebola virus disease. Under the terms of the original license agreement Lumos Pharma is entitled to retain 60% of the value of the PRV. Based upon an agreed valuation of $100 million Merck will pay Lumos $60 million. The transaction remains subject to customary closing conditions, including anti-trust review.
“We are pleased to announce the sale of the PRV, which will provide an important source of non-dilutive capital to fund additional investment in our pipeline and the evaluation of other assets for potential acquisitions or partnerships. These efforts will be critical to our growth over the coming year, and we are committed to our strategic priority of becoming leaders in the rare and ultra-rare disease space,” said Rick Hawkins, Chairman, CEO and President. “Additionally, we are looking forward to initiating our Phase 2b trial of our lead candidate LUM-201 in patients with Pediatric Growth Hormone Deficiency, or PGHD, prior to the end of 2020. We believe we have the opportunity to greatly improve the standard of care for patients impacted by this disease. If approved, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment.”
Jefferies LLC. acted as exclusive financial advisor to Lumos Pharma, Inc. on this transaction.
Financial Guidance Update Related to PRV Sale
The total valuation of the PRV in the transaction was $100 million. Lumos Pharma will receive approximately $60 million which represents the Company’s 60% interest in the total value of the PRV. The $60 million will be received in two non-contingent payments, $34 million in 2020 and $26 million in the first quarter of 2021. The non-dilutive funds from this transaction will provide additional capital to support the expansion of its pipeline through the in-licensing or acquisition of another novel therapeutic candidate for those suffering from rare diseases. These funds are in addition to the Company’s cash position as of March 31, 2020 which was anticipated to be sufficient to support the Company’s current operations through the Phase 2b clinical trial read-out.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding by leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit www.lumos-pharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of Lumos Pharma, Inc. (the “Company”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “forecast,” “projected,” "guidance," "upcoming," "will," "plan," “intend,” "anticipate," "approximate," "expect," “potential,” “imminent,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, the potential of an orally administered treatment regimen for PGHD and other indications, and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes due to a number of important factors, including the effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic and other risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements as discussed in "Risk Factors" and elsewhere in Lumos Pharma’s definitive proxy statement, as amended and filed with the SEC on February 13, 2020, Lumos Pharma’s Annual Report on Form 10-K for the year ended December 31, 2019 and other reports filed with the SEC. The forward-looking statements in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause their views to change. However, while it may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing either of the Company’s views as of any date subsequent to the date of this press release.
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-648-3757
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
Related Articles
More articles issued by Lumos Pharma, Inc.
More articles related to:
Company Announcement
Profile
Lumos Pharma, Inc.
Subscribe via RSS
Subscribe via ATOM
Javascript
Austin, Texas, UNITED STATES
https://lumos-pharma.com/
Lumos Pharma Inc (LUMO)
Intraday
3 Month
6 Month
1 Year
Last: $14.23
Change: -0.12
% Change: -0.84%
Volume: 7K
Open: $14.15
Previous Close: $14.35
Low: $14.11
High: $14.25
Market Cap: 0
Shares Outs.: 0
EPS: 0.00
P/E Ratio: -
Dividend: N/A
Yield: N/A
52 Week Low: $6.74
52 Week High: $17.50
Quote delayed at least 20 mins.
Media Files
lumos.png
Logo Download Options lumos.png
LOGO URL | Copy the link below
http://www.globenewswire.com/attachment-download-view/2068182/867339/4/1/0/867339.png
Tags
BIOTECHNOLOGYHEALTHMEDICALPHARMACEUTICALS
Newswire Distribution Network & Management
Home
Newsroom
RSS Feeds
Legal
About Us
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
© 2020 GlobeNewswire, Inc. All Rights Reserved.
We use cookies to improve your GlobeNewswire experience. By continuing, you agree to our use of cookies. For more information, please see our Privacy Policy.
Ok
CTYX your posts are all copy paste bro. Try some DD for once rather than relying on scaring newbies with Bag holding threats.
CTYX going to $1.00 Light up another Doobie Sccoobie.
CTYX PRV's can be sold here is one MERCK bought for $60M. I mean everyones heard of Merck right? They have a big office I hear.
http://www.globenewswire.com/news-release/2020/07/27/2068182/0/en/Lumos-Pharma-Announces-Sale-of-Priority-Review-Voucher.html
July 27, 2020 16:05 ET | Source: Lumos Pharma, Inc.
AUSTIN, Texas, July 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that it has entered into a definitive agreement to sell its Priority Review Voucher (PRV) to Merck, known as MSD outside the United States and Canada.
The PRV was granted in conjunction with the approval by the U.S. Food and Drug Administration (FDA) of ERVEBO®, a vaccine developed by the Company’s licensee, Merck, for the prevention of the Zaire Ebola virus disease. Under the terms of the original license agreement Lumos Pharma is entitled to retain 60% of the value of the PRV. Based upon an agreed valuation of $100 million Merck will pay Lumos $60 million. The transaction remains subject to customary closing conditions, including anti-trust review.
“We are pleased to announce the sale of the PRV, which will provide an important source of non-dilutive capital to fund additional investment in our pipeline and the evaluation of other assets for potential acquisitions or partnerships. These efforts will be critical to our growth over the coming year, and we are committed to our strategic priority of becoming leaders in the rare and ultra-rare disease space,” said Rick Hawkins, Chairman, CEO and President. “Additionally, we are looking forward to initiating our Phase 2b trial of our lead candidate LUM-201 in patients with Pediatric Growth Hormone Deficiency, or PGHD, prior to the end of 2020. We believe we have the opportunity to greatly improve the standard of care for patients impacted by this disease. If approved, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment.”
Jefferies LLC. acted as exclusive financial advisor to Lumos Pharma, Inc. on this transaction.
Financial Guidance Update Related to PRV Sale
The total valuation of the PRV in the transaction was $100 million. Lumos Pharma will receive approximately $60 million which represents the Company’s 60% interest in the total value of the PRV. The $60 million will be received in two non-contingent payments, $34 million in 2020 and $26 million in the first quarter of 2021. The non-dilutive funds from this transaction will provide additional capital to support the expansion of its pipeline through the in-licensing or acquisition of another novel therapeutic candidate for those suffering from rare diseases. These funds are in addition to the Company’s cash position as of March 31, 2020 which was anticipated to be sufficient to support the Company’s current operations through the Phase 2b clinical trial read-out.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding by leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit www.lumos-pharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of Lumos Pharma, Inc. (the “Company”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “forecast,” “projected,” "guidance," "upcoming," "will," "plan," “intend,” "anticipate," "approximate," "expect," “potential,” “imminent,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, the potential of an orally administered treatment regimen for PGHD and other indications, and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes due to a number of important factors, including the effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic and other risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements as discussed in "Risk Factors" and elsewhere in Lumos Pharma’s definitive proxy statement, as amended and filed with the SEC on February 13, 2020, Lumos Pharma’s Annual Report on Form 10-K for the year ended December 31, 2019 and other reports filed with the SEC. The forward-looking statements in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause their views to change. However, while it may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing either of the Company’s views as of any date subsequent to the date of this press release.
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-648-3757
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
CTYX now with 2 Drug Therapies. Rabies and Brain Cancer. Also Orphan Designation as well as PVR for the Tropical Disease PVR they can sell for $125M to $200M No Debt no Dilution. Great Shares structure Great CEO with long ties to Pharma and Big pharma in Japan Not some bullshit China Pharma but Japan.
So what ya doing working a Glory Hole?
Rabies&Cancer Fluff? Drop the crack pipe and slap the ask.
CTYX Woo Baby Got Rabies Drug and now The Cancer Drug! Go Long now I guess?
$CTYX is Orphan Drug Company not COVID-19 That isnot the Focus as COVID-19 Vaccines would not be an orphan Drug. Please stop trying to tie this to COVID as that's not the Focus. Pretty Obvious that the PRV is the Focus to raise funds, and the Rabies Treatment for World-Wide partnerships
$CTYX been here since this came off Grey MArket 1/3/20 CEO Paul Michaels is top notch CEO. No Debt and Zero Dilution. CTYX has access to plenty of private funding from Japan as well as other markets. No need to raise money diluting stock for pennies.
ENRT DD of NDA's even
better
ENRT Been here 1yr DD Spot on
ENRT DD on sticky and intro Box. Feel free to read it.
$ENRT DD Sticky added for phone traders
ENRT Big DD post:
Enertopia Ticker ENRT
Lithium Mining in Nevada
Patented Process
Website: https://www.enertopia.com
Corp Twitter Account: @enertopiacorp
Share Structure
Link to 8-K with NDA: https://www.sec.gov/Archives/edgar/data/1346022/000106299320004817/exhibit99-1.htm
Location of ENRT Project on Nevada Map:
Map of Mine Location and other Mines Nearby:
Tesla GigaFactory Location:
Claims with Enertopia:
NDA Press release October 7th 2020:
CORP Slide Deck
https://www.enertopia.com/wp-content/uploads/2020/01/January-2020-Enertopia-Corporate-Presentation-.pdf
TESLA Battery Engineers working on new Lighter Stronger Batteries.
https://electrek.co/2020/08/12/tesla-researchers-show-path-next-gen-battery-cell-breakthrough-energy-density/
CEO interview on ENRT Lithium processing:
$ENRT Ibox Full of DD scroll up if you need the DD.
$ENRT INFO BOX UPDATED
ENRT Working in it now
$ENRT thanks putting that in the iBox
$ENRT will need to update the iBox with new info. No Change to SS, No Debt or Dilution. Patent and NDA with Big Company. Buy out possible.
$ENRT They own a patented procedure for extracting more Lithium with Less acid. That is worth a bunch.
$ENRT Few Links on Tesla Battery work
https://electrek.co/2020/08/12/tesla-researchers-show-path-next-gen-battery-cell-breakthrough-energy-density/
$ENRT awesome news on the NDA.
$JADA Then the Royal We @ZH gunna get their Back Blowed out
$JADA that made me Snort. Good one!
CTYX 5MN Volume Day